Prosecution Insights
Last updated: April 19, 2026

Sangamo Therapeutics Inc.

5 pending office actions

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18337861 Compositions and Methods for Producing Recombinant AAV LI, BAO Q 1671 Final Rejection Jun 20, 2023
18249418 GENERATION OF CD4+ EFFECTOR AND REGULATORY T CELLS FROM HUMAN PLURIPOTENT STEM CELLS WESTON, ALYSSA G 1633 Non-Final OA Apr 18, 2023
18029806 METHODS OF DETECTING ANTI-AAV ANTIBODIES HILL, MYRON G 1671 Non-Final OA Mar 31, 2023
17791395 ZINC FINGER PROTEIN TRANSCRIPTION FACTORS FOR REPRESSING TAU EXPRESSION HELLMAN, KRISTINA M 1654 Non-Final OA Jul 07, 2022
17766083 Zinc Finger Protein Transcription Factors for Treatment of Prion Disease HUMPHRIES, NICHOLAS ADAM 1631 Non-Final OA Apr 01, 2022

Managing Sangamo Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month